Navigation Links
Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com : Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia
Date:10/28/2008

Harvest Technologies Corp. (www.harvesttech.com) announced today that its new patient-education website, www.CLIclinicalstudy.com, is now “live”. The site is intended to offer persons who are considering enrolling in the Company’s clinical trial and their referring physicians important information related to the study’s design, the science that underlies it, and the location of the study’s sites.

PLYMOUTH, Mass. (Business Wire EON) October 28, 2008 -- The Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to Harvest Technologies to conduct a randomized, controlled, double-blind, multicenter clinical trial using the Company's BMAC System to prepare a composition of bone marrow stem cells to treat patients with Critical Limb Ischemia (CLI). This "feasibility trial" will enroll a total of 48 subjects. Subjects who enroll in this study have exhausted all surgical and procedural options and are at extreme risk for major amputation. The BMAC System is a point-of-care device for concentrating a patient's own (autologous) bone marrow stem cells in approximately 15 minutes at the bedside. The clinical study design provides for injecting these cells into the affected limb to reduce the potential for limb amputation. It also will offer data with respect to the safety of this procedure.

This U.S. clinical study is being led by Principal Investigator Mark D. Iafrati, M.D., Chief of Vascular Surgery at Tufts Medical Center, Boston. In addition, the CLI Study is also enrolling subjects at: Roper St. Francis Healthcare, Charleston, S.C.; Methodist Hospital, Houston; University of South Florida Health, Tampa, Fla.; Maimonides Medical Center, Brooklyn, N.Y.; and Vascular Associates of Albany, Albany, N.Y.

Published studies in this area have used complicated methods to process and concentrate adult stem cells from a patient's bone marrow. The BMAC System is the first to offer clinicians a simple, easy point-of-care method to prepare a concentration of stem and precursor cells from a small aspirate of autologous bone marrow in just 15 minutes.

Harvest Technologies is a privately held company based in Plymouth, Mass.

Read the full story at http://www.prweb.com/releases/harvest_technologies/bmac_system/prweb1539624.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. 2008 Idaho Potato Harvest Forecast: Plentiful, High-Quality Spuds
2. MAQUET Cardiovascular Responds to Terumo Complaint About VASOVIEW Endoscopic Vessel Harvesting Systems
3. Americas Second Harvest Provides Emergency Food and Water to Tropic Storm Fay Evacuees
4. Fresh Harvest Products, Inc. Announces New Brand Initiative
5. New Technique Harvests Stem Cells at Earlier Stage
6. American Red Cross Honors Americas Second Harvest at Heritage of Service Dinner
7. CalbaTech Announces $999,926 Reduction in Debt; First Adult Stem Cell Harvesting Scheduled
8. Quaker Introduces Simple Harvest(TM) All Natural Multigrain Chewy Granola Bars That Taste Simply Delicious
9. Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System
10. StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System
11. Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com :  Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia 
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: